|Day Low/High||170.53 / 171.93|
|52 Wk Low/High||130.09 / 181.81|
Facebook (FB) smashed earnings expectations--again. Shares are hitting record highs in the pre-market.
Stocks remain very unconcerned about rates, despite the odds of a fall increase slightly rising.
Amgen (AMGN) reported 2016 second quarter earnings after the closing bell today that beat analysts' expectations.
TheStreet highlights 3 stocks pushing the drugs industry higher today.
Amgen investors have had a rough ride. The stock is down about 3% year to date, but the second half of the year could get interesting.
Cramer is no fan of Chesapeake Energy and thinks Gartner has great growth.
Buying Yahoo!'s core assets is the start of something very big, Cramer says.
Amgen (AMGN) will report 2016 second quarter earnings on Wednesday, July 27 after the market close.
The Federal Reserve will steal focus from another onslaught of earnings in the coming week as investors remain wary over the central bank's rate-hike timetable.
Based on Phase 3 FRAME Study in Postmenopausal Women With Osteoporosis
If you want to know what an overbought market looks like, this is it.
A late-stage trial for Amgen’s (AMGN) drug ABP 980 shows its ‘non-inferiority’ to Roche’s (RHHBY) biosimilar branded product.
Exclusive Agreement Includes Nine Biosimilars
TheStreet highlights 3 stocks pushing the health services industry lower today.
A look at who will be up and who will down this earnings season.
First Amgen Biosimilar Candidate and Adalimumab Biosimilar Candidate to be Reviewed by U.S. FDA Advisory Committee
Repatha® (evolocumab) Pushtronex™ System Available to U.S. Patients in Early August
You have to be impressed by the breadth of XNCR's pipeline and significant partnerships with major players.
Juno Therapeutics reminds investors yet again that the business of biotech -- developing new medicines that are effective and reasonably safe -- is hard to get right.
Goldman Sachs expects "rising uncertainty" in the second half of 2016 and suggests that investors stick to stocks within defensive sectors including consumer, health care and telecom services.
The company's shares were up nearly 2% in after hours trading.
Traders and investors should either stand aside or start probing the short side.
Head-to-Head Phase 3 Trial Demonstrated Superiority of Kyprolis and Dexamethasone Over Velcade® (Bortezomib) and Dexamethasone in Patients with Relapsed Multiple Myeloma
Trade-Ideas LLC identified Amgen (AMGN) as a "storm the castle" (crossing above the 200-day simple moving average on higher than normal relative volume) candidate